P-ISSN 2587-2400 | E-ISSN 2587-196X
EJMO Volume : 4 Issue : 4 Year : 2020
EJMO. 2020; 4(2): 172-176 | DOI: 10.14744/ejmo.2020.15578

Irinotecan and Ifosfamide Combination is an Effective and Safe Option in Patients with Refractory Small Cell Lung Cancer: A Retrospective Cross-Sectional Study

Mustafa Karaagac1, Mehmet Artac1, Sema Sezgin Goksu2, Melek Karakurt Eryilmaz1, Hasan Senol Coskun2, Hakan Bozcuk2
1Department of Medical Oncology, Necmettin Erbakan University, Meram Medical Faculty, Konya, Turkey, 2Department of Medical Oncology, Akdeniz University, Faculty of Medicine, Antalya, Turkey

Objectives: Recurrent and progressive small cell lung cancer (SCLC) has a very poor prognosis, and treatment options are limited. Combination of irinotecan with ifosfamide ( I-I regimen) in SCLC has limited preliminary data. In this study, we aimed to evaluate the efficacy and toxicity of I-I regimen in patients with previously treated SCLC. Methods: A total of 25 patients were retrospectively reviewed. Ifosfamide dose was 1500 mg/m2/ per day, days 1-3, irinotecan 80 mg/m2 per day days 1.8 and 15 every four weeks. Results: Median age of patients was 55 years (range 42-80). Median chemotherapy cycles were 3 (range 1-7). The frequency of the second, third and fourth line treatments were 68%, 24%, and 8% respectively. Partial remission was obtained in 15 patients (60%) and complete remission in one patient (4%). Median progression free survival (PFS) and overall survival (OS) figures were 7.8 and 11.1 months, respectively. Granulocyte colony stimulating factor (G-CSF) was used in 40% of patients. Grade 3-4 anemia, leukopenia, and thrombocytopenia were seen in 20%, 36% and 12% of these cases, respectively. Conclusion: Ifosfamide and irinotecan combination is an effective and a tolerable treatment option for patients with platinum refractory SCLC. Keywords: Chemotherapy, ifosfamide, irinotecan, small cell lung cancer, survival


Cite This Article

Karaagac M, Artac M, Sezgin Goksu S, Karakurt Eryilmaz M, Coskun H, Bozcuk H. Irinotecan and Ifosfamide Combination is an Effective and Safe Option in Patients with Refractory Small Cell Lung Cancer: A Retrospective Cross-Sectional Study. EJMO. 2020; 4(2): 172-176

Corresponding Author:

Full Text PDF PDF Download
EJMO & EJMO